Actively Recruiting
Phase II Study of Dysplasix17 Intravaginal Suppositories for Women With High-Risk HPV and Mild Cervical Cell Changes ASC-US or LSIL
Led by Amplexd Therapeutics, Inc. · Updated on 2026-05-14
45
Participants Needed
1
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of an investigational vaginal suppository therapy called Dysplasix12 in women with high-risk human papillomavirus hr-HPV infection and mild cervical cell abnormalities, specifically Atypical Squamous Cells of Undetermined Significance ASC-US or Low-Grade Squamous Intraepithelial Lesions LSIL. This Phase II, double-blind, placebo-controlled study aims to find out if the therapy can help shrink cervical lesions, clear hr-HPV infection, and assess any side effects that may occur. Participants will be randomly assigned to receive either Dysplasix12 suppositories containing Epigallocatechin gallate and Quinine Sulfate or a placebo suppository. They will self-administer 15 doses intravaginally over 19 days in three cycles of five consecutive nights with two-day breaks between cycles. If menstruation occurs, use will pause until it ends and then continue until all doses are completed. The study includes screening for HPV and cervical abnormalities, followed by treatment and safety monitoring. During the study, participants will attend clinic visits for examinations, HPV testing, cytology tests, and safety assessments up to 50 days after enrollment. They will keep a daily diary to record suppository use and any effects. Researchers will evaluate cervical lesion changes, HPV clearance, and monitor for any adverse events using established criteria. The total study participation lasts about two months, including treatment and follow-up visits.
CONDITIONS
Brief Title
Phase II Study of Dysplasix™ Intravaginal Suppositories in Patients Patients With High-Risk HPV and Mild Cervical Cytologic Abnormalities
Research Team
T
Trial Manager
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here